Promising new treatments, particularly Vorasidenib, which has shown significant benefits in enhancing progression-free survival and prolonging the time to the next intervention in patients with grade 2 IDH-mutant glioma [18]. This evidence concerns the gene IDH1 and central nervous system cancer.